“New research by investigators at the University of California, San Francisco and the Children’s National Health System, has provided early evidence that liquid biopsy testing could help doctors monitor how well treatments are working in kids with diffuse midline gliomas.
“Brain cancers present a challenge for longitudinal monitoring, because obtaining repeat biopsy samples is dangerous and difficult. But liquid biopsy techniques have now opened the possibility of tracking these and other tumors over time based on analysis of tumor genetic material that is shed into the blood or other body fluids.”
“In a phase II study reported in the Journal of Clinical Oncology, Grill et al found that the addition of bevacizumab (Avastin) to radiotherapy plus temozolomide (RT + TMZ) did not improve event-free survival in pediatric patients with newly diagnosed high-grade glioma.
“In the international open-label study, 121 patients aged 3 to 18 years with localized nonbrainstem disease from 51 sites in 14 countries were randomized between October 2011 and February 2015 to receive RT + TMZ with (n = 62) or without (n = 59) bevacizumab 10 mg/kg every 2 weeks. RT + TMZ consisted of RT at 1.8 Gy 5 days per week and TMZ at 75 mg/m2 per day for 6 weeks followed by a 4 weeks off, then up to twelve 28-day cycles at 150 mg/m2 per day on days 1 to 5 in cycle 1 and 200 mg/m2 per day on days 1 to 5 in cycles 2 to 12. The primary endpoint was event-free survival on blinded central radiology review. Results are reported as of 12 months after the enrollment of the last patient.”
“Researchers at Johns Hopkins University are conducting the first clinical trials to evaluate the potential of a pinworm medication for the treatment of children and adults with newly diagnosed glioblastoma.
“Mebendazole has been used for more than 40 years to treat parasitic infections.
“Although the medication requires further testing in patients with cancer, results of a phase 1 trial have shown the medication is safe for and tolerated by adults with glioblastoma. An additional phase 1 trial is underway to assess the agent in children.”
“Results from a large clinical study showed that testing pediatric brain tumors for genetic abnormalities is feasible and could play a role in guiding patients’ treatment.
“The study, published in Neuro-Oncology, showed that more than half of the samples taken from pediatric brain tumors and analyzed using genomic profiling had genetic irregularities that could influence how the disease was diagnosed or treated with approved drugs or agents being evaluated in clinical trials.”
Los Altos, California – January 25, 2017 – Cancer Commons, a nonprofit network of physicians, scientists and patients dedicated to helping each patient achieve the best possible outcome, announces the launch of a new program to identify personalized treatment options for children with brain cancer. The program is funded by a generous lead gift from Sheri Sobrato Brisson, a pediatric brain tumor survivor and advocate for children with serious illness, and her husband Eric Brisson.
“We are motivated to help children with brain cancer by giving their physicians and families access to the best treatment plans,” shares Sheri Sobrato Brisson. “Diagnosis is a frightening time, and patients and their families need help to quickly sort through vast, confusing amounts of information to assure them that they are making the best possible choices.” Continue reading…
“A team of Dana-Farber scientists has released new research with an important message about precision medicine: Sequencing the genes of brain tumors in kids could point to treatments that target their genetic abnormalities and therefore have the best chance of being effective. At least one of those drugs is already on the market, Novartis’ Tafinlar (dabrafenib), approved by the FDA to treat other types of cancer but still readily available to pediatric oncologists who may want to try it in their patients.”
“Melanoma is an aggressive form of skin cancer that has been increasing in incidence in adults over the past 40 years. Although pediatric melanoma is rare (5-6 children per million), most studies indicate that incidence has been increasing. In a new study scheduled for publication in The Journal of Pediatrics, researchers found that the incidence of pediatric melanoma in the United States actually has decreased from 2004-2010.
“Laura B. Campbell, MD, and colleagues from Case Western Reserve University and University Hospitals (UH) Case Medical Center in Cleveland, used data from the Surveillance, Epidemiology, and End Results cancer registries, which represent approximately 28% of the US population, to identify new cases of pediatric melanoma from 2000-2010. According to Dr. Campbell, “We took an in-depth look at whether or not the number of new cases of melanoma per year in children and adolescents was increasing in the recent decade.” They also studied how rates changed over time according to age, sex, type of melanoma, and its location on the body.
“A total of 1,185 new cases of pediatric melanoma were identified. Overall, the number of new cases each year decreased by 12% per year from 2004-2010. For boys, there was a decrease of almost 7% each year (2000-2010); in 15-19-year-olds, there was a decrease of 11% each year (2003-2010). Additionally, new cases of pediatric melanoma located on the trunk and upper extremities, as well as cases with good prognostic indicators, both decreased significantly each year.”